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Endocytosed cholesterol must be transferred from the environment (e.g., low-density lipoproteins) via the
lysosomal system to the rest of the cell. In Niemann-Pick type C disease, this process fails. In a recent issue
of Cell, Kwon et al. (2009) suggest how this transpires mechanistically by crystallizing a domain of a protein
defective in this syndrome.
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PreviewsThe failure to appropriately mobilize hy-
drophobic lipids in the mammalian lyso-
some can frequently be of devastating
consequence. Patients suffering from
one such defect, Niemann-Pick type C
(NP-C) disease, generally succumb by
their second decade of life, with a virtual
absenceof cerebellar functiondue to lyso-
somal accumulation of sphingolipids and
LDL-derived cholesterol (Figure 1). Muta-
tions in two genes,Npc1 (encoding a lyso-
somal transmembrane protein; Carstea
et al., 1997) and Npc2 (encoding a lyso-
somal lumen protein; Naureckiene et al.,
2000), independently confer 95% and
5% of NP-C disease cases, respectively.
As is too often the case, the isolation of
the disease genes has not provided a
treatment or, until recently, even amecha-
nism by which low-density lipoprotein
(LDL)-derived cholesterol traverses the
lysosomal/endosomal network.
In a tour de force of papers, culminating
in the current work (Kwon et al., 2009),
Infante, Goldstein, Brown, and Kwon
have characterized cholesterol binding by
the NPC proteins and thereby concep-
tualize a model for the movement of LDL-
derived cholesterol within and perhaps
beyond the lysosome. In so doing, they
have firmly established the NP-C disease
pathway as a functional component of the
LDL-receptor network of endocytosed
cholesterol utilization. These studies
emanated from the surprising observation
that sterol binding by NPC1 is accom-
plished by an NH2-terminal ‘‘soluble’’
domain of the protein, unique to this
gene family (Infante et al., 2008). In the
current study, the crystal structures ofboth apo- and ligand-associated forms
of this domain (NPC1(NTD), residues 23–
247; Figure 1) are defined. The crux of
the proposed model rests upon the
manner in which cholesterol is orientated
in NPC1(NTD) and NPC2 asmirror images
of each other. This implicates a head-to-
tail donation of cholesterol between these
proteins, followed by its transfer into the
lysosomal membrane.
Kwon and colleagues also performed
saturation mutagenesis of NPC1(NTD)
and identified distinct subdomains within
NPC1(NTD) that bind cholesterol from
NPC2 or transfer cholesterol to liposomes
in vitro. Such mutants failed to comple-
ment lipid egress inNpc1/mutant cells,
thus confirming the physiological rele-
vance of NPC1(NTD) (Kwon et al., 2009).
Amino acid identity in human, chimp,
dog, cow, mouse, and yeast at 6 of 14
residues in NPC1(NTD) critical to choles-
terol binding suggests a primordial need
for binding sterols in the lysosome.
Accordingly, the functions of orthologs
separated by more than 2 billion years
of evolution (e.g., yeast Ncr1p and
human NPC1; Malathi et al., 2004) are
apparently indistinguishable. Surpris-
ingly, only 6 of the 14 critical cholesterol-
binding sites are identical between human
NPC1(NTD) and its paralog, NPC1L1. In
contrast to binding cholesterol, transfer
is a less-conserved process, as only 2
out of 11 of these sites are conserved
from yeast Ncr1p to human NPC1 and
NPC1L1.
The studies by Infante and colleagues
were made with a relatively modest
portion (17%) of the NPC1 molecule,Cell Metabthus begging the questions: What is the
rest of the molecule for, and are there
other domains that bind sterols or
other lipids? The other regions of NPC1
must have critical functions, given that
NPC1(NTD) only contains 20 of the 241
disease mutations in NPC1 (Figure 1;
inventoried in NPC-db http://npc.fzk.de).
Prior to characterization of NPC1(NTD),
the favored culprit for binding or respond-
ing to cholesterol was the sterol-sensing
domain (SSD; residues 615–797; Fig-
ure 1). In common with similar domains
in other proteins, the NPC1(SSD) has the
potential to modulate protein-protein
interactions in response to sterol levels.
The Dallas model for handoff of choles-
terol from NPC2 to NPC1 provides the
first kinetic rationale to a longstanding
hypothesis that there is a physical interac-
tion between NPC2 and NPC1. Surpris-
ingly, such interactions have been elusive
and are presumably transient. To date,
the only reported interaction of NPC1 is
a cholesterol-mediated physical associa-
tion with SKD1 (Ohsaki et al., 2006),
a protein implicated in endosome-to-
lysosome transport.
Under standard conditions, cholesterol
crosses membranes by simple equilibra-
tion. This passive process is often cata-
lyzed by energy-consuming membrane
transporters, such as ATP-binding cas-
sette proteins (e.g., ABCA1 and ABCG1).
These chemical and genetic processes
must be hindered in NP-C disease. For
example, it is possible that the glycocalyx
at the inner surface of the limiting mem-
brane of the lysosome (as proposed
by Kolter and Sandhoff, 2005) or theolism 10, July 8, 2009 ª2009 Elsevier Inc. 3
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PreviewsFigure 1. Schematic Representation of the NPC1 Protein and the Biochemical Hallmark of Niemann-Pick Type C Disease
This structure (redrawn from Davies and Ioannou, 2000) emphasizes the domain-like nature of NPC1 and distinguishes the NPC1(NTD) characterized by Kwon
et al. (2009) with a dashed line. Speculative domains are indicated by the different colors. The sterol-sensing domain (SSD) has been characterized by mutagen-
esis and conservation with other related proteins. Chinese hamster ovary cells stained for cholesterol (filipin) and sphingolipids (cholera toxin B, CTB) show
increased intracellular accumulation of these metabolites in NPC1 mutant cells. Accumulation of these lipids is the result of any one of 241 mutations distributed
across the NPC1 protein. The number of mutations in each structural ‘‘domain’’ is indicated in parentheses adjacent to the respective domain. Images are cour-
tesy of Ann Gale and Katsumi Higaki.LBPA-enriched membranes of the multi-
vesicular bodies (Kobayashi et al., 1999)
may impede the free trafficking of choles-
terol out of this organelle. Thus, even in the
case of ‘‘normal’’ cholesterol transport
from NPC2 to NPC1, an additional barrier
must still be negotiated. Cyclodextrin,
a cholesterol-binding agent, re-estab-
lishes normal and effective sterol egress
even when the NPC1 and NPC2 proteins
are dysfunctional (Liu et al., 2009).
Perhaps the beneficial effects of cyclo-
dextrin act at the glycocalyx or LBPA
barrier? It is further possible that an as
yet unidentified NP-C disease candidate
(proposed by the authors of the current
study) may activate the membrane-
traversing forces, be enhanced by cyclo-
dextrin, and/or represent the molecular
sites at which NP-C phenotypes can be
induced with progesterone and hydro-
phobic amines.
An ongoing debate is whether choles-
terol is the primary ligand for NPC1
and whether sphingolipids are mere by-4 Cell Metabolism 10, July 8, 2009 ª2009 Elstanders that secondarily accumulate.
If sphingolipids are not ligands for
NPC1(NTD) or any other part of NPC1,
then the argument for primary accumula-
tion of cholesterol due to defective NPC1
would be favored. Similarly, do the N-
terminal domains of family members,
such as yeast Ncr1p or human NPC1L1,
display similar ligand binding as a conse-
quence of sequence conservation? In
essence, the cumulative research by the
group at Dallas has finally validated the
longstanding prediction that NPC1 binds
and transports sterols. In so doing, the
field has at last advanced to amechanistic
phase.
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